New Products Drove Medtronic's Q2 Revenues

The company?s string of new products released over the past year helped boost the top line in the second quarter. The trend is expected to continue in the near term on account of Medtronic's strong product pipeline across each of its segments. The synergies resulting from the smooth integration of the Covidien acquisition offset a decline in gross margins, leading to a 20 basis point improvement in the company?s non-GAAP operating margin in constant currency terms.